Mucosal and Systemic Immune Responses: Design and Evaluation of Novel Enveloped Vaccines

Mucosal and Systemic Immune Responses: Design and Evaluation of Novel Enveloped Vaccines

  • Jun 4, 2012
  • Mass Bio, Cambridge, MA

Anthony Cristillo, Ph.D., Associate Director of Product Development of ABL, Inc. presented recent work at MassBio, 300 Technology Square, 8th Floor, Cambridge, MA on Monday, June 4th.

Agenda

7:30 a.m. to 8:30 a.m. Breakfast

8:30 a.m. to 9:45 a.m. Presentation

9:45 a.m. to 10:30 a.m. Q/A

An HIV-1 vaccine that has envelope proteins expressed with sustained protein spikes on the cell surface and exposes masked epitopes may produce antibody responses of greater magnitude and breadth. For this study, a more stable HIV-1 envelope was designed by introducing sequence changes in the cytoplasmic tail of the envelope protein gp41. In vitro and in vivo evaluations were then conducted to measure enhanced immune responses to the stable envelope.

The second part of the presentation will focus on augmentation of immune responses following HIV-1 vaccination containing adjuvants or immunomodulatory agents. Mucosal and systemic immune responses of two novel inulin-based adjuvant formulations and an E3 ligase were tested in mice.

About ABL

Advanced BioScience Laboratories, Inc. (ABL) is a Maryland-based biomedical contract research and manufacturing organization dedicated to advancing the development of therapeutics, vaccines and other biologic products. ABL has extensive experience working with diverse organizations, including various government and academic entities and commercial bio/pharmaceutical companies. Notable services include basic research, product design, process and assay development, preclinical in vivo models (including immunomonitoring), and Phase I/II cGMP biologics manufacturing. Since 2001 ABL has been a part of the Institut Mérieux, a group of companies dedicated to developing translational science for better patient care globally. For more information on ABL and our services, please visit our website at www.ablinc.com.